NCT06559007

Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Dose HRS-5041 in Healthy Caucasian Male Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Atridia Pty Ltd. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a phase 1, open-label, randomized study. The objective of this study is to evaluate the PK, safety and tolerability of orally administered single-dose HRS-5041 in healthy Caucasian male participants.

Detailed description

The objective of this study is to evaluate the PK, safety and tolerability of orally administered single-dose HRS-5041 in healthy Caucasian male participants.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	HRS-5041 dose level 1	Single dose of HRS-5041 orally administered
DRUG	HRS-5041 dose level 2	Single dose of HRS-5041 orally administered

Timeline

• Start date: 2024-09-25
• Primary completion: 2025-01-06
• Completion: 2025-03-03
• First posted: 2024-08-19
• Last updated: 2025-03-18

Locations

1 site across 1 country: Australia